Ainos, Inc.

As of March 8, 2024, Ainos, Inc. is considered overvalued with poor financial metrics, including negative earnings and high debt, resulting in a significant decline in its valuation outlook compared to peers and an underperformance of -40.17% against the S&P 500.

As of June 6, 2025, Ainos, Inc. shows a mildly bullish trend driven by daily moving averages, though caution is advised due to bearish weekly MACD and KST indicators, resulting in a mixed outlook with potential volatility.

Ainos, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $3 million as of March 2025. It has a market cap of $11.17 million, with key metrics indicating a loss-making status and a debt-to-equity ratio of 0.71.

As of Jun 18, Ainos, Inc. has a market capitalization of 11.17 million, with net sales of 0.11 million and a net profit of -14.84 million over the last four quarters. As of Dec 24, the company reported shareholder's funds of 15.52 million and total assets of 28.82 million.